NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $3.89 -0.15 (-3.71%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$3.94 +0.05 (+1.41%) As of 10/30/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aquestive Therapeutics Stock (NASDAQ:AQST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$3.86▼$4.0550-Day Range$3.78▼$5.3952-Week Range$2.93▼$6.87Volume2.41 million shsAverage Volume2.08 million shsMarket Capitalization$488.23 millionP/E RatioN/ADividend YieldN/APrice Target$8.60Consensus RatingModerate Buy Company Overview Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms. Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis. The company also markets Sympazan (clobazam oral film) for certain patients with Lennox-Gastaut syndrome. In addition to its commercial products, Aquestive is advancing a pipeline of oral film medicines and product candidates intended to address conditions in areas such as neurology, emergency medicine, and other specialty-care markets. The company serves primarily the U.S. market and has pursued partnerships and licensing opportunities to expand the use of its drug-delivery technology.AI Generated. May Contain Errors. Read More Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreAQST MarketRank™: 2.064608571055 of 5 starsAquestive Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 684th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAquestive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAquestive Therapeutics has a consensus price target of $8.60, representing about 121.1% upside from its current price of $3.89.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Aquestive Therapeutics are expected to remain at ($0.50) per share in the coming year.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.59% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 13.88, which indicates bearish sentiment.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 4.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.64 News SentimentAquestive Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aquestive Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $271,675.00 in company stock.Percentage Held by Insiders6.81% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by Institutions32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQST Stock News HeadlinesAquestive Therapeutics (NASDAQ:AQST) Stock Breaks Above 200-Day Moving Average - Time to Sell?October 29 at 3:21 AM | americanbankingnews.comAquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ETOctober 27, 2026 | globenewswire.comThree oil giants buried the same discovery for 50 yearsIn 1976, a Chevron drilling team tapped an energy source powerful enough to run a city, then buried the project. Unocal and Texaco confirmed the same results and shelved them too. One company spent 60 years perfecting the technology Big Oil walked away from. Google signed a 15-year contract, and Bill Gates wrote a 100 million dollar check. On November 17th, a new government policy hands this company an edge no other energy source receives.October 31 at 1:00 AM | Behind the Markets (Ad)Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Average Target Price of $8.60October 27, 2026 | americanbankingnews.comAquestive Therapeutics Updates Corporate Governance BylawsOctober 19, 2026 | tipranks.comAquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares of StockOctober 17, 2026 | insidertrades.comAquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating UpgradeOctober 16, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and TransMedics Group (TMDX)October 16, 2026 | theglobeandmail.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $6.46 at the beginning of the year. Since then, AQST shares have decreased by 39.8% and is now trading at $3.89. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.08. The company earned $13.82 million during the quarter, compared to analyst estimates of $11.42 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $68 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,500,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' top institutional investors include Profund Advisors LLC (0.16%), China Universal Asset Management Co. Ltd. and Mirae Asset Global Investments Co. Ltd. (0.01%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender, A Ernest Toth Jr, Peter E Boyd, Carl N Kraus, Cassie Jung, Melina Cioffi, Sherry Korczynski and Julie Krop. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Plug Power (PLUG), Tesla (TSLA), Advanced Micro Devices (AMD), NIO (NIO), Viking Therapeutics (VKTX) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/11/2026Today10/31/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AQST's financial health is in the Green zone, according to TradeSmith. AQST has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees147Year Founded2004Price Target and Rating Average Price Target for Aquestive Therapeutics$8.60 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+121.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.78 million Net Margins-144.63% Pretax Margin-144.63% Return on EquityN/A Return on Assets-52.40% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio6.74 Sales & Book Value Annual Sales$44.54 million Price / Sales10.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-13.89Miscellaneous Outstanding Shares125,510,000Free Float116,965,000Market Cap$488.23 million OptionableOptionable Beta1.49 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:AQST) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
